Skip to main content
Equibles

Manuel C. Alves-Aivado, M.D., Ph.D.

Board Member

Rein Therapeutics, Inc. (RNTX)

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Manuel C. Alves-Aivado, M.D., Ph.D.

Manuel C. Alves-Aivado, M.D., Ph.D. is recorded as Board Member at Rein Therapeutics, Inc. (RNTX). Rein Therapeutics, Inc. reported in an 8-K filed February 19, 2026 that Manuel C. Alves-Aivado, M.D., Ph.D. resigned as member of the Board of Directors, effective February 16, 2026. Rein Therapeutics, Inc. reported in an 8-K filed March 15, 2024 that Manuel C. Alves-Aivado, M.D., Ph.D. resigned as Chief Executive Officer, effective March 11, 2024. Rein Therapeutics, Inc. reported in an 8-K filed February 29, 2024 that Manuel C. Alves-Aivado, M.D., Ph.D. was appointed Class III director, effective February 28, 2024.

“On February 16, 2026, Manuel C. Alves Aivado, M.D., Ph.D., notified Rein Therapeutics, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”), effective immediately.”
Rein Therapeutics, Inc. Form 8-K, filed February 19, 2026 · Read the filing
“On March 11, 2024, Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), and Manuel C. Alves-Aivado, M.D., Ph.D., agreed that his employment with the Company would cease and he would resign from his position as Chief Executive Officer of the Company, effective as of March 11, 2024 (the “Separation Date”).”
Rein Therapeutics, Inc. Form 8-K, filed March 15, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Rein Therapeutics, Inc.

Other people whose current roles at this company are on record from its filings.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.